Oddi G, De Angelis G, Alma M G, De Marinis F, Bigioni D
Servizio di Anatomia ed Istologia Patologica, USL RM/10, Ospedale C. Forlanini, Roma.
Minerva Med. 1993 Apr;84(4):179-82.
The authors take into consideration 19 cases of lung neoplasm to see the relationship of clinical behaviour and C219. They found a cutoff (25%) to separate drug resistant by drug sensibility. Marker sensitivity was 84.2% and relation with PCNA was negative (-0.384).
作者纳入19例肺肿瘤病例以观察临床行为与C219之间的关系。他们通过药敏试验找到了一个区分耐药性的临界值（25%）。标志物敏感性为84.2%，与增殖细胞核抗原（PCNA）的相关性为阴性（-0.384）。
